These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19624459)

  • 1. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.
    Berber E; James PD; Hough C; Lillicrap D
    J Thromb Haemost; 2009 Oct; 7(10):1672-9. PubMed ID: 19624459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.
    Hickson N; Hampshire D; Winship P; Goudemand J; Schneppenheim R; Budde U; Castaman G; Rodeghiero F; Federici AB; James P; Peake I; Eikenboom J; Goodeve A;
    J Thromb Haemost; 2010 Sep; 8(9):1986-93. PubMed ID: 20492463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.
    O'Brien LA; James PD; Othman M; Berber E; Cameron C; Notley CR; Hegadorn CA; Sutherland JJ; Hough C; Rivard GE; O'Shaunessey D; Lillicrap D;
    Blood; 2003 Jul; 102(2):549-57. PubMed ID: 12649144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.
    Schneppenheim R; Budde U; Obser T; Brassard J; Mainusch K; Ruggeri ZM; Schneppenheim S; Schwaab R; Oldenburg J
    Blood; 2001 Apr; 97(7):2059-66. PubMed ID: 11264172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
    Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
    Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
    Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
    Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity.
    Hilbert L; Jorieux S; Proulle V; Favier R; Goudemand J; Parquet A; Meyer D; Fressinaud E; Mazurier C;
    Br J Haematol; 2003 Feb; 120(4):627-32. PubMed ID: 12588349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2N von Willebrand disease: Characterization and diagnostic difficulties.
    Casonato A; Galletta E; Sarolo L; Daidone V
    Haemophilia; 2018 Jan; 24(1):134-140. PubMed ID: 29115006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization.
    Jorieux S; Gaucher C; Goudemand J; Mazurier C
    Blood; 1998 Dec; 92(12):4663-70. PubMed ID: 9845532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common splice site mutation is shared by two families with different type 2N von Willebrand disease mutations.
    Nesbitt IM; Hampton KK; Preston FE; Peake IR; Goodeve AC
    Thromb Haemost; 1999 Sep; 82(3):1061-4. PubMed ID: 10494764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
    Kroner PA; Foster PA; Fahs SA; Montgomery RR
    Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3.
    Sutherland MS; Cumming AM; Bowman M; Bolton-Maggs PH; Bowen DJ; Collins PW; Hay CR; Will AM; Keeney S
    Blood; 2009 Jul; 114(5):1091-8. PubMed ID: 19372260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A noncanonical splicing variant c.875-5 T > G in von Willebrand factor causes in-frame exon skipping and type 2A von Willebrand disease.
    Liang Q; Zhang Z; Ding B; Shao Y; Ding Q; Dai J; Hu X; Wu W; Wang X
    Thromb Res; 2024 Apr; 236():51-60. PubMed ID: 38387303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
    Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
    J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene.
    Casonato A; Gaucher C; Pontara E; Zucchetto A; Zerbinati P; Mazurier C; Girolami A
    Br J Haematol; 1998 Oct; 103(1):39-41. PubMed ID: 9792286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common VWF exon 28 haplotype in the Turkish population.
    Berber E; Pehlevan F; Akin M; Capan OY; Kavakli K; Çaglayan SH
    Clin Appl Thromb Hemost; 2013 Sep; 19(5):550-6. PubMed ID: 22473027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease.
    Gallinaro L; Sartorello F; Pontara E; Cattini MG; Bertomoro A; Bartoloni L; Pagnan A; Casonato A
    Thromb Haemost; 2006 Dec; 96(6):711-6. PubMed ID: 17139363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.